血管内皮生长因子抑制后糖尿病牵拉性视网膜膜中的细胞凋亡与血管纤维化:前瞻性试验结果 第2号报告
研究纳入19例患者20只眼,随机分为玻璃体腔注射贝伐珠单抗组10只眼和对照组10只眼,在玻璃体切割术中获取纤维血管性视网膜前膜。结果显示两组均见高水平纤维化,贝伐珠单抗组膜内细胞凋亡较对照组高(P=0.05),CD31-CTGF及细胞角蛋白-VEGF共定位呈非显著降低。贝伐珠单抗抑制玻璃体VEGF水平,但未显著改变糖尿病膜中VEGF或CTGF。
要点
- 贝伐珠单抗组膜内细胞凋亡较对照组高(P=0.05)。
- 两组均观察到高水平纤维化。
- 贝伐珠单抗组CD31-CTGF及细胞角蛋白-VEGF共定位较对照组呈非显著降低。
核心结论
- 贝伐珠单抗抑制玻璃体VEGF水平,但未显著改变糖尿病膜中VEGF或CTGF,可能归因于高基线纤维化水平。
- 贝伐珠单抗可能引起纤维血管膜内细胞凋亡。
研究设计与样本
- 前瞻性试验,纳入19例患者20只眼,随机分为玻璃体腔注射贝伐珠单抗组10只眼和对照组10只眼。
- 在玻璃体切割术中获取纤维血管性视网膜前膜,采用免疫荧光共聚焦显微镜进行定量及共定位分析,并行Masson三色染色、苏木精-伊红切片细胞计数及末端dUTP缺口末端标记染色。
主要发现
- 两组均观察到高水平纤维化。
- 贝伐珠单抗组膜内细胞凋亡较对照组高(P=0.05)。
- 贝伐珠单抗组CD31-CTGF及细胞角蛋白-VEGF共定位较对照组呈非显著降低。
- 提取膜中VEGF与玻璃体VEGF水平呈正相关;提取膜中CTGF与玻璃体CTGF水平呈负相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We sought to characterize the angiofibrotic and apoptotic effects of vascular endothelial growth factor (VEGF)-inhibition on fibrovascular epiretinal membranes in eyes with traction retinal detachment because of proliferative diabetic retinopathy. METHODS: Membranes were excised from 20 eyes of 19 patients (10 randomized to intravitreal bevacizumab, 10 controls) at vitrectomy. Membranes were stained with antibodies targeting connective tissue growth factor (CTGF) or VEGF and colabeled with antibodies directed against endothelial cells (CD31), myofibroblasts, or retinal pigment epithelium markers. Quantitative and colocalization analyses of antibody labeling were obtained through immunofluorescence confocal microscopy. Masson trichrome staining, cell counting of hematoxylin and eosin sections, and terminal dUTP nick-end labeling staining were performed. RESULTS: High levels of fibrosis were observed in both groups. Cell apoptosis was higher (P = 0.05) in bevacizumab-treated membranes compared with controls. The bevacizumab group had a nonsignificant reduction in colocalization in CD31-CTGF and cytokeratin-VEGF studies compared with controls. Vascular endothelial growth factor in extracted membranes was positively correlated with vitreous levels of VEGF; CTGF in extracted membranes was negatively correlated with vitreous levels of CTGF. CONCLUSION: Bevacizumab suppresses vitreous VEGF levels, but does not significantly alter VEGF or CTGF in diabetic membranes that may be explained by high baseline levels of fibrosis. Bevacizumab may cause apoptosis within fibrovascular membranes.
引用
- Jiao C, Eliott D, Spee C, et al. APOPTOSIS AND ANGIOFIBROSIS IN DIABETIC TRACTIONAL MEMBRANES AFTER VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITION: Results of a Prospective Trial. Report No. 2. Retina. 2019. PMID: 29190236. doi:10.1097/IAE.0000000000001952
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。